Optimizing Therapy for Patients with Advanced Renal Cell Carcinoma - Episode 9

Managing AEs in Cabo Nivo Combination Therapy for Advanced RCC

, , , , ,

Expert oncologists discuss the nuances of managing toxicities associated with Cabozantinib and Nivolumab combination therapy for advanced renal cell carcinoma (RCC).

EP. 1: Overview on Advanced RCC: Epidemiology, Presentation, and Risk Stratification
EP. 2: Frontline Therapy for Advanced Renal Cell Carcinoma: Patient Scenario Discussion
EP. 3: Imaging and Staging Considerations in Renal Cell Carcinoma
EP. 4: Frontline Therapy for Renal Cell Carcinoma: Choosing the Right Regimen
EP. 5: Treatment Strategies for Non-Clear Cell Renal Cell Carcinoma
EP. 6: Comparing Treatment Combinations in Renal Cell Carcinoma
EP. 7: Key Decision Factors in Selecting Frontline Therapy for Metastatic RCC
EP. 8: Sequencing and Second-Line Therapy in RCC: Patient Scenario
Now Viewing
EP. 9: Managing AEs in Cabo Nivo Combination Therapy for Advanced RCC
EP. 10: Navigating Toxicity Discussions With Patients With Renal Cell Carcinoma
EP. 11: Novel Therapies for Advanced RCC: LITESPARK-005 and Treatment Sequencing
EP. 12: Triple Combination Therapies in RCC: Clinical Trial Insights
EP. 13: Key Takeaways: Advancements and Challenges in Kidney Cancer Treatment

Related Content:

Optimizing Therapy for Patients with Advanced Renal Cell CarcinomaHuntsman Cancer Institute at the University of Utah The University of Texas MD Anderson Cancer Center
Venetoclax Plus 10-Day Decitabine Produces Responses in High-Risk MDS, AML
FDA Approval Insights: Zolbetuximab for CLDN18.2+ HER2-Negative Gastric and GEJ Adenocarcinoma
RP1 Plus Nivolumab Is Active, Safe in Advanced Melanoma After Progression on Anti–PD-1 Therapy